

Supplementary material for:

Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis

Shaun Nielsen*^{1,2}, Bronwen Needham², Steven T. Leach³, Andrew S. Day⁴, Adam Jaffe^{3,5}, Torsten Thomas^{1,2}, Chee Y. Ooi*^{3,6}

¹Centre for Marine Bio-innovation, ²School of Biotechnology and Biomolecular Sciences, and
³Discipline of Paediatrics, School of Women's and Children's Health, Medicine, University of New South Wales, Sydney, 2052, Australia

⁴Department of Paediatrics, University of Otago, Christchurch, 8011, New Zealand


⁵Department of Paediatric Respiratory and ⁶Department of Paediatric Gastroenterology, Sydney Children's Hospital, Randwick, 2031, Australia

* Corresponding authors


E-mail: s.nielsen@unsw.edu.au, keith.ooi@hongyee.org

Tel: +61 2 9385 2741


Supplementary figures.




Supplementary Figure 1. The number of OTUs (97 % similarity) given the number of 16S rRNA gene sequences sampled per stool sample. a) samples from healthy vs CF comparisons with 20 008 total sequences per stool, b) samples from the pancreatic status comparison with 9751 total sequences per stool sample.



Supplementary Figure 2. Within-subject variability of a) the Log₁₀ number of OTUs and b) the Shannon-Weaver index of diversity with the CF cohort. Subjects are connected by blue lines with the second sample symbol unfilled, and show within-variability is within the normal variability observed within the cohort for both alpha-diversity measures.



Supplementary Figure 3. Patterns of abundances of OTUs showing interactions between the covariates age and CF condition (based on F values > 5). The figure shows the different relationship types between age and the abundance of OTUs in gut microbiomes communities from CF and healthy (HC) children. Fitted lines are constructed from general linear models. Letters in square brackets following taxonomic names denote the lowest level of taxonomic classification, G = genus, F = family, O = order, C = class.



Supplementary Figure 3. Patterns of abundances of OTUs showing relationships with the covariates age and CF condition (based on F values > 5). The figure shows similar relationships between age and the abundance of OTUs in gut microbiomes communities from CF and healthy (HC) children. Fitted lines are constructed from general linear models. Letters in square brackets following taxonomic names denote the lowest level of taxonomic classification, G = genus, F = family, O = order, C = class.

Supplementary tables.

Sample	Included_in_analysis	Treatment	SampleTime	Age	ID	FEV1%predicted	Tobramycin (nebulised)	Piperacillin	colomycin/ Collistin	Itracconazole	Fluconazol	prednisolone	Azithromycin	Flucloxacillin/ Flopen	Augmentin Duo	amoxycillin	1. Antibiotics	2a. S. aureus prophylaxis	2b. S. aureus prophylaxis (0-3/5 year vs Long-term)	3. H. influenzae	4. Pseudomonas aeruginosa	5a. Other microorganisms	5b. Specify 5a
14	Y	CF	1	2.66	50a	o	.	.	o	o	o	o	.	.	o	
26	Y	CF	1	2.76	41a	o	o	.	.	o	o	o	o	o	o	o	
35	Y	CF	1	3.06	48a	o	.	.	o	o	o	o	o	o	o	
21	Y	CF	1	3.63	52b	o	.	.	o	o	o	o	o	.	o	
50	Y	CF	1	3.76	47b	o	.	.	o	o	o	o	o	o	o	
76	Y	CF	1	4.93	71a	96	o	.	.	o	o	o	o	o	o	o	
24	Y	CF	1	5.72	43a	97	o	.	.	o	o	o	o	o	o	o	
2	Y	CF	1	5.86	3b	93	o	.	.	o	o	o	o	o	.	o	
19	Y	CF	1	6.19	44a	93	o	.	.	o	o	o	.	o	o	o	
56	Y	CF	1	7	12a	97	o	.	.	o	o	o	.	o	.	o	
23	Y	CF	1	7.12	35b	11	o	.	.	o	o	o	o	o	o	o	
84	Y	CF	1	8.17	32a	86	o	.	.	o	o	o	.	o	o	o	
52	Y	CF	1	9	15a	64	o	.	.	o	o	o	o	o	o	o	
78	Y	CF	1	9.8	27b	86	o	o	o	.	o	o	o	o	o	o	o	
41	Y	CF	1	9.82	34b	10	o	.	.	o	o	.	o	.	o	o	
20	Y	CF	1	11.5	8b	11	o	.	.	o	o	.	.	o	o	o	
74	Y	CF	1	11.6	16b	10	o	.	.	o	o	.	o	o	o	o	
70	Y	CF	1	12.3	28a	84	o	.	.	o	o	.	o	.	o	o	
43	Y	CF	1	12.4	30b	99	o	.	.	o	o	o	.	o	o	o	
47	Y	CF	1	13	14a	88	o	o	.	.	o	.	.	o	o	o	o	
34	Y	CF	1	13.9	7b											o							
66	Y	CF	1	16.1	26a	72	o	.	.	o	o	.	.	o	.	o	
27	Y	CF	1	17.3	10b	12	o	o	o	.	o	o	o	o	o	o	o	
72	Y	CF	3	1.46	51a	o	.	.	o	o	o	o	.	o	o	
71	N	CF	2	9	15b											o	o	o	o	o	o	o	
86	N	CF	2	11	30a	10	o	.	.	o	o	o	o	.	o	o	
87	N	CF	2	9.38	32b	95	o	.	.	o	o	.	.	o	o	o	
51	N	CF	2	5	35a	10	o	.	.	o	o	o	o	o	o	o	
90	N	CF	2	3.5	47a	o	.	.	o	o	o	o	o	o	o	
45	N	CF	2	3.92	48b	o	o	.	.	o	o	o	o	o	o	o	
89	N	CF	2	1.63	51b	o	.	.	o	o	o	o	.	o	o	

Supplementary Table 1. Antibiotic use within the CF cohort (o = Yes and . = No, empty cells = No data)